Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA3893537
Max Phase: Preclinical
Molecular Formula: C21H25ClN6O4S
Molecular Weight: 492.99
Molecule Type: Small molecule
Associated Items:
ID: ALA3893537
Max Phase: Preclinical
Molecular Formula: C21H25ClN6O4S
Molecular Weight: 492.99
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: C=CCNS(=O)(=O)c1cc(-c2c(C)nc3c(NCCNC(C)=O)cc(Cl)nn23)ccc1OC
Standard InChI: InChI=1S/C21H25ClN6O4S/c1-5-8-25-33(30,31)18-11-15(6-7-17(18)32-4)20-13(2)26-21-16(12-19(22)27-28(20)21)24-10-9-23-14(3)29/h5-7,11-12,24-25H,1,8-10H2,2-4H3,(H,23,29)
Standard InChI Key: GRHQJOYUBHIACN-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 492.99 | Molecular Weight (Monoisotopic): 492.1347 | AlogP: 2.38 | #Rotatable Bonds: 10 |
Polar Surface Area: 126.72 | Molecular Species: NEUTRAL | HBA: 8 | HBD: 3 |
#RO5 Violations: 0 | HBA (Lipinski): 10 | HBD (Lipinski): 3 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: 9.47 | CX Basic pKa: 3.20 | CX LogP: 1.07 | CX LogD: 1.07 |
Aromatic Rings: 3 | Heavy Atoms: 33 | QED Weighted: 0.29 | Np Likeness Score: -1.55 |
1. Mejdrová I, Chalupská D, Plačková P, Müller C, Šála M, Klíma M, Baumlová A, Hřebabecký H, Procházková E, Dejmek M, Strunin D, Weber J, Lee G, Matoušová M, Mertlíková-Kaiserová H, Ziebuhr J, Birkus G, Boura E, Nencka R.. (2017) Rational Design of Novel Highly Potent and Selective Phosphatidylinositol 4-Kinase IIIβ (PI4KB) Inhibitors as Broad-Spectrum Antiviral Agents and Tools for Chemical Biology., 60 (1): [PMID:28004945] [10.1021/acs.jmedchem.6b01465] |
Source(1):